This is an international site for Exjade® (Deferasirox) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional I am a patient inside of the US I am a patient outside the U.S.

Home > Transfusion-Dependent β-Thalassemia > Overview
Print
Transfusion-Dependant Beta-Thalassemia

In β-thalassemia patients with iron toxicity

EXJADE Provides
Efficacious Total
Body Chelation

Thalassemia is the most common genetic disorder, with an annual birth rate of 94 million for infants who are heterozygous for β-thalassemia and of 60,000 for those who are homozygous.1 Chronic blood transfusions treat the underlying anemia but may lead to iron toxicity.1

EXJADE provides efficacious therapy regardless of cardiac iron loading

Patients with mild-moderate, severe, and no cardiac iron loading benefited from appropriately dosed EXJADE.

Learn more about patients with mild to moderate iron loading

Learn more about patients with severe iron loading

Learn more about patients with no cardiac iron loading

Learn more about the powerful chelation provided by EXJADE


The Thalassemia International Federation recommends screening for iron toxicity.
Or visit http://www.thalassaemia.org.cy/publications.html

Screening for Iron Toxicity: Thalassemia International Federation Recommendations2
  • Track transfusions
    • Patients who have received 10 to 20 lifetime transfusions are at risk of iron toxicity
  • Screen serum ferritin
    • Serum ferritin levels that are consistently >1000 µg/L are indicative of iron toxicity

References

  1. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
  2. Cappellini MD, Cohen A, Eleftherlou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia. 2nd ed. Thalassaemia International Foundation; 2008.

LEARN ABOUT THE CONSEQUENCES
OF IRON TOXICITY IN
β-THALASSEMIA



Learn more

TRANSFUSION-DEPENDENT
β-THALASSEMIA		 MYELODYSPLASTIC SYNDROMES SICKLE CELL DISEASE APLASTIC AND OTHER ANEMIAS TOOLS AND RESOURCES ALL ABOUT EXJADE

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with β-thalassemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusion in patients aged 2 years and older with β-thalassemia major or other anemias when deferoxamine is contraindicated or inadequate.
Disclaimer: This is an international website for Exjade, and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
© Novartis AG | Use of this website is subject to our Terms of Use | About Novartis Oncology | Privacy | Site Map | Contact Us | EU SmPC | Safety Information | PubMed